NextCell Pharma AB (STO:NXTCL)
Sweden · Delayed Price · Currency is SEK 1.448
-0.200 (-12.14%)
Jan 21, 2026, 5:24 PM CET
NextCell Pharma AB Company Description
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden.
Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes.
The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.
NextCell Pharma AB
| Country | Sweden |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Mathias Svahn |
Contact Details
Address: Karolinska Institutet Science Park Huddinge, Stockholm County 141 57 Sweden | |
| Phone | 46 87 35 55 95 |
| Website | nextcellpharma.com |
Stock Details
| Ticker Symbol | NXTCL |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | September - August |
| Reporting Currency | SEK |
| ISIN Number | SE0009723125 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sofie Falk Jansson | Chief Executive Officer of Cellaviva |
| Lindsay Davies | Chief Scientific Officer and Chief Executive Officer of QVance |
| Dr. Mathias Svahn Ph.D. | Founder and Chief Executive Officer |
| Edvard Smith | Chief Medical Officer and Director |
| Sofia Sisay | Head of Clinical Trials |